Terms: = Breast cancer AND FOXA1, TCF3A, 3169, ENSG00000129514, P55317, HNF3A, MGC33105
377 results:
1. Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.
Joosten SEP; Gregoricchio S; Stelloo S; Yapıcı E; Huang CF; Yavuz K; Donaldson Collier M; Morova T; Altintaş UB; Kim Y; Canisius S; Moelans CB; van Diest PJ; Korkmaz G; Lack NA; Vermeulen M; Linn SC; Zwart W
Genome Res; 2024 May; 34(4):539-555. PubMed ID: 38719469
[TBL] [Abstract] [Full Text] [Related]
2. The role of transcription factor foxa1/C2/M1/O3/P1/Q1 in breast cancer.
Yuan H; Liang Y; Hu S; Chen J; You J; Jiang J; Luo M; Zeng M
Medicine (Baltimore); 2024 Apr; 103(15):e37709. PubMed ID: 38608123
[TBL] [Abstract] [Full Text] [Related]
3. Clinically-observed foxa1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract] [Full Text] [Related]
4. Identification of lineage-specific epigenetic regulators foxa1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
[TBL] [Abstract] [Full Text] [Related]
5. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract] [Full Text] [Related]
6. Staufen1 Represses the foxa1-Regulated Transcriptome by Destabilizing foxa1 mRNA in Colorectal cancer Cells.
Pasterczyk KR; Li XL; Singh R; Zibitt MS; Hartford CCR; Pongor L; Jenkins LM; Hu Y; Zhao PX; Muys BR; Kumar S; Roper N; Aladjem MI; Pommier Y; Grammatikakis I; Lal A
Mol Cell Biol; 2024; 44(2):43-56. PubMed ID: 38347726
[TBL] [Abstract] [Full Text] [Related]
7. PMM2 controls ERα levels and cell proliferation in ESR1 Y537S variant expressing breast cancer cells.
Cipolletti M; Acconcia F
Mol Cell Endocrinol; 2024 Apr; 584():112160. PubMed ID: 38266771
[TBL] [Abstract] [Full Text] [Related]
8. Deciphering the Immune Microenvironment at the Forefront of Tumor Aggressiveness by Constructing a Regulatory Network with Single-Cell and Spatial Transcriptomic Data.
Xu K; Yu D; Zhang S; Chen L; Liu Z; Xie L
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254989
[TBL] [Abstract] [Full Text] [Related]
9. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature.
Gonzalez T; Nie Q; Chaudhary LN; Basel D; Reddi HV
Cancer Genet; 2024 Apr; 282-283():1-8. PubMed ID: 38134587
[TBL] [Abstract] [Full Text] [Related]
10. foxa1 forms biomolecular condensates that unpack condensed chromatin to function as a pioneer factor.
Ji D; Shao C; Yu J; Hou Y; Gao X; Wu Y; Wang L; Chen P
Mol Cell; 2024 Jan; 84(2):244-260.e7. PubMed ID: 38101414
[TBL] [Abstract] [Full Text] [Related]
11. Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel.
Yan K; Niu L; Wu B; He C; Deng L; Chen C; Lan Z; Lin C; Kuang W; Lin H; Zou J; Zhang W; Luo Z
Ann Med; 2023; 55(2):2280708. PubMed ID: 37967237
[TBL] [Abstract] [Full Text] [Related]
12. Architecture and topologies of gene regulatory networks associated with breast cancer, adjacent normal, and normal tissues.
Kumar S; Vindal V
Funct Integr Genomics; 2023 Oct; 23(4):324. PubMed ID: 37878223
[TBL] [Abstract] [Full Text] [Related]
13. Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Iwamoto T; Niikura N; Watanabe K; Takeshita T; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
Breast Cancer Res Treat; 2024 Jan; 203(2):225-234. PubMed ID: 37875670
[TBL] [Abstract] [Full Text] [Related]
14. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial.
Lundgren C; Tutzauer J; Church SE; Stål O; Ekholm M; Forsare C; Nordenskjöld B; Fernö M; Bendahl PO; Rydén L
Breast Cancer Res; 2023 Sep; 25(1):110. PubMed ID: 37773134
[TBL] [Abstract] [Full Text] [Related]
15. Epigenetic reprogramming of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung adenocarcinoma.
Abatti LE; Lado-Fernández P; Huynh L; Collado M; Hoffman MM; Mitchell JA
Nucleic Acids Res; 2023 Oct; 51(19):10109-10131. PubMed ID: 37738673
[TBL] [Abstract] [Full Text] [Related]
16. A Druggable foxa1-Glucocorticoid Receptor Transcriptional Axis Drives Tumor Growth in a Subset of Non-Small Cell Lung cancer.
Dorso M; Patel PT; Pankov A; Boyer JA; Soni RK; Del Priore IS; Hayatt O; Kulick A; Hagen CJ; de Stanchina E; Junttila MR; Daemen A; Friedman LS; Hendrickson RC; Chandarlapaty S
Cancer Res Commun; 2023 Sep; 3(9):1788-1799. PubMed ID: 37691854
[TBL] [Abstract] [Full Text] [Related]
17. foxa1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.
Liu Y; Yu K; Kong X; Zhang K; Wang L; Zhang N; Chen Q; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Sci Adv; 2023 Aug; 9(33):eadg7112. PubMed ID: 37595040
[TBL] [Abstract] [Full Text] [Related]
18. AGR2 and foxa1 as prognostic markers in ER-positive breast cancer.
Zhou M; Gan XL; Ren YX; Chen QX; Yang YZ; Weng ZJ; Zhang XF; Guan JX; Tang LY; Ren ZF
BMC Cancer; 2023 Aug; 23(1):743. PubMed ID: 37568077
[TBL] [Abstract] [Full Text] [Related]
19. Pan-cancer analyses reveal multi-omic signatures and clinical implementations of the forkhead-box gene family.
Bi X; Zheng D; Cai J; Xu D; Chen L; Xu Z; Cao M; Li P; Shen Y; Wang H; Zheng W; Wu D; Zheng S; Li K
Cancer Med; 2023 Aug; 12(16):17428-17444. PubMed ID: 37401400
[TBL] [Abstract] [Full Text] [Related]
20. Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive breast cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Ding Y; Mo W; Xie X; Wang O; He X; Zhao S; Gu X; Liang C; Qin C; Ding K; Yang H; Ding X
Oncol Res Treat; 2023; 46(7-8):303-311. PubMed ID: 37302393
[TBL] [Abstract] [Full Text] [Related]
[Next]